Introduction {#S1}
============

In humans, more than 100 trillion microorganisms colonize the gastrointestinal tract establishing mutualistic relationships with the host ([@B25]). Metagenomic data indicate that gram-negative bacteroidetes (17--60%) and gram positive firmicutes (35--80%) are the most predominant phyla in healthy individuals ([@B3]; [@B9]). Changes in the bacterial species, the so-called dysbiosis, resulting in the loss of intestinal homeostasis, have been described in different intestinal disorders, including Inflammatory Bowel Diseases (IBD) and Irritable Bowel Syndrome (IBS) ([@B52]; [@B60]). IBD, consisting of ulcerative colitis (UC), and Crohn's disease (CD), are chronic, relapsing-remitting, gastrointestinal inflammatory disease which associate with various degrees of intestinal damage, and can promote development of local and extra-intestinal complications ([@B77]). The incidence and prevalence of IBD are highest in westernized nations, with reported hightest prevalence values in Europe of 322 for CD and 505 for UC per 100,000 persons ([@B46]; [@B50]). The prevalence of IBD exceeded 0.3% in North America, Oceania, and many countries in Europe. The changing nature of IBD, including relapsing and remitting stages, along with potential disease complications can also lead to psychological symptoms of anxiety, and depression ([@B50]). Although the pathogenesis of IBD is not fully understood, several lines of evidence support the hypothesis that IBD occur in genetically susceptible subjects as a result of an abnormal immune response to autologous bacterial flora following exposure to multiple environmental factors ([@B70]; [@B29]). It has also been hypothesized that a breakdown in the balance between putative protective species and "harmful" species could contribute to IBD pathogenesis ([@B34]). For instance, many studies have documented reduced bacterial diversity and richness in IBD patients, largely due to decrease of firmicutes and increase of Bacteroidetes phyla ([@B43], [@B42]; [@B76]; [@B51]).

Irritable bowel syndrome is one of the most common functional gastrointestinal disorders worldwide. Global prevalence, based on Rome III criteria, was estimated at 10--15% ([@B40]). Recent studies using the more restrictive Rome IV criteria ([@B37]; [@B38]), point to lower prevalence rates of 5--6% ([@B33]; [@B73]).

Irritable bowel syndrome is characterized by abdominal pain or discomfort, bloating, and altered bowel habits. Increasing evidence suggests an important role of the intestinal microbiota in the pathophysiology of IBS ([@B31]; [@B36]; [@B45]). Support for this comes from the observation that IBS can develop after intestinal infection and efficacy of probiotics in the management of IBS patients ([@B16]; [@B21]).

To understand the interactions between microbiota, metabolic processes, and pathophysiology it is important to elucidate specific microbial signatures of IBS and IBD.

The aim of this study was to investigate the differences in fecal and mucosal-associated microbiota richness and composition among IBD, IBS patients along with healthy controls (CTRLs), to better define if each disorder have its own microbiota signature. An additional aim of this study was to evaluate potential 16S rRNA gene amplicons biomarkers for IBD and IBS by comparison of taxonomic composition, allowing to predict the bacteria that concisely differentiate among the groups being compared, or to identify the alterations shared.

Materials and Methods {#S2}
=====================

This prospective, multicenter study was conducted on patients with diagnosis of IBD or IBS compared to healthy subjects (CTRLs), consecutively enrolled at the Gastroenterology Unit of the Tor Vergata Hospital and the Department of Gastroenterology of Campus Biomedico University of Rome between 2015 and 2017.

Study Population {#S2.SS1}
----------------

A complete demographic and clinical evaluation of patients and CTRLs was performed by a Gastroenterologist during the first visit of enrollment.

Below the inclusion and exclusion criteria for patients and CTRLs:

1.  IBD patients:

    Inclusion criteria: (1) Diagnosis of IBD for at least 3 months according to standard Montreal classification ([@B63]). (2) Patients with IBD with colic or ileocolic localization. (3) Patients aged 25--60 years.

    Exclusion criteria: (1) Use of antibiotics or any other probiotic bacterial supplement in the previous 3 months. (2) Use of non-steroidal anti-inflammatory drugs (NSAIDs) in the previous 3 months. (3) Reported recent diagnosis (less than 3 months) of bacterial or parasitic infections of the gastrointestinal tract.

2.  IBS patients:

    Inclusion criteria: diagnosis of IBS performed by using the following diagnostic-therapeutic procedures: clinical evaluation and blood/stool test; questionnaire of intestinal functional disorders, elaborated according to the Rome IV criteria ([@B37]; [@B38]); colonoscopy (RSCS) with multiple biopsies.

    Exclusion criteria: (1) Use of antibiotics or any other probiotic bacterial supplement in the previous 3 months. (2) Use of NSAIDs in the previous 3 months. (3) Reported recent diagnosis (less than 3 months) of bacterial or parasitic infections of the gastrointestinal tract. (4) Severe psychiatric disease as the dominant clinical problem. (5) Other severe diseases, and a history of drug or alcohol abuse.

3.  CTRLs

    Inclusion criteria: (1) Gastrointestinal asymptomatic subjects (using a questionnaire to exclude chronic diseases and any current gastrointestinal symptoms). (2) Up to 60 years of age who undergo colonoscopy for colorectal cancer screening. (3) Absence of macroscopic lesions (including the presence of *diverticulae*). (4) Absence of microscopic lesions evident on the histological examination of colonic biopsy samples taken during the colonoscopy. The CTRLs exclusion criteria were the same described for IBS.

Study Protocol and Sample Collections {#S2.SS2}
-------------------------------------

At the baseline visit all the enrolled patients underwent endoscopic examination of the lower digestive tract conducted to explore the cecum, after preparation with polyethylene glycol (PEG) (4 l) and a low fiber diet 3 days prior to endoscopy. Mucosal biopsies were collected from sigmoid colon in all of patients and CTRLs for the routine histological examinations and for the microbiome assessment. In IBD patients, in relation to disease localization, we collected biopsies from the injured mucosa for routine histological examinations and microbiome assessment.

Moreover, when applicable, only for microbiome assessment, in IBD patients was collected an additional biopsy from macroscopic healthy mucosa, by sampling the healthy upstream colon segment. All patients collected a stool sample the day before the preparation with PEG. All biopsies and fecal samples were immediately stored at −80°C, until processing to strictly prevent anaerobic bacteria from being exposed to oxygen and to avoid bacterial overgrowth before DNA extraction.

DNA Extraction, Amplification for Pyrosequencing, Statistical Analysis {#S2.SS3}
----------------------------------------------------------------------

All mucosal and fecal samples were submitted to DNA extraction. DNA from mucosal samples (approximately 1 mm × 2 mm) was automatically extracted by the EZ1 biorobot using EZ1 DNA tissue kit following manufacturer's instructions (Qiagen, Germany). Fecal DNA was manually extracted, starting from 200 mg of feces, by the QIAamp DNA Stool Mini Kit (Qiagen, Germany). The V1-V3 regions (520 bp) of the 16S ribosomal RNA locus were amplified for the next pyrosequencing step on a 454- Junior Genome Sequencer (Roche 454 Life Sciences, Branford, CT, United States), according to the pipeline described in [@B18] and [@B18]. Primers were barcoded by 8 unique nucleotide sequences (Roche 454 Life Sciences, Branford, CT, United States). The polymerase chain reactions were performed, starting from 0.5 ng of DNA, using a Hi-Fi PCR Taq polymerase (FastStart^TM^ High Fidelity PCR System, dNTPack, Roche Diagnostics, Mannheim, Germany), guaranteeing high specificity, sensitivity and accuracy during PCR amplification. Amplicon DNA were quantified by Quant-iT PicoGreen dsDNA kit (Life Technologies Corporation, Oregon, United States) following the manufacturer's instructions, and then pooled in equal concentrations, prior the sequencing reactions. The 454 amplicon signal processing was applied to subtract background and normalize the images process and to transform the captured images into read flowgrams and basecalls with associated per-base quality scores (GS sequencer software v. 2.7, Roche Diagnostics, Mannheim, Germany). The pre-processed reads was trimmed on the base of ends signal quality and to exclude and the adaptor sequences (GS sequencer software v. 2.7, Roche Diagnostics). Raw sequences, obtained from each single sample, were analyzed by using QIIME 1.9.0 software ([@B8]). In order to guarantee a higher level of accuracy in terms of operational taxonomic units (OTUs) detection, after demultiplexing, reads with an average quality score lower than 25, shorter than 300 bp, and with an ambiguous base calling were excluded from the analysis. Sequences that passed the quality filter were denoised ([@B59]) and singletons were excluded. The denoised sequences were chimera-checked by *identify_chimeric_seqs.py* using both Blast_fragments and ChimeraSlayer^[1](#footnote1){ref-type="fn"}^ approaches. The OTUs defined by a 97% of similarity were *de novo* picked (*pick_de_novo_otus.py*) and the representative sequences were submitted to PyNAST for the sequence alignment ([@B8]), and to UCLUST for sequence clustering ([@B17]). The database for OTUs matching was greengenes (v 13.8). This script produces an OTU mapping file (*pick_otus.py*), a representative set of sequences (*pick_rep_set.py*), a sequence alignment file (*align_seqs.py*), taxonomy assignment file (*assign_taxonomy.py*), a filtered sequence alignment (*filter_alignment.py*), a phylogenetic tree (*make_phylogeny.py*) and a biom-formatted OTU table (*make_otu_table.py*). After rarefying (rarefaction sequences counts: 2870 sequences for stool samples and 980 sequences for tissue samples), the alpha diversity analysis was performed for both fecal and biopsy sample groups. The β-diversity tests by unweighted and weighted UniFrac metrics were carried out by QIIME software using *beta_diversity_through_plots.py* and plotted by PCoA plot; PERMANOVA test with 999 permutations was applied to unweight and weighted UniFrac distance matrices (*compare_categories.py*); the *group_significance.py* script was used to perform Kruskal-Wallis test to compare OTU frequencies across samples ([@B48]). Taxonomic levels phylum and genus/species were studied, and raw *p* value \<0.05 and false discovery rate adjusted P (pFDR) \< 0.05 were considered as statistically significant.

All sequencing data associated with this study were uploaded to the NCBI bioproject database: [PRJNA391149](PRJNA391149)^[2](#footnote2){ref-type="fn"}^.

Comparison of Taxonomic Composition According to Disease Status by LEfSe for 16S rRNA-Based Metagenomic Biomarker {#S2.SS4}
-----------------------------------------------------------------------------------------------------------------

Linear discriminant analysis effect size (LEfSe) ([@B65]), an algorithm used to discover high-dimensional biomarkers characterizing the differences between biological conditions, to identify taxa that differed consistently between sample types, was used for 16S rRNA gene amplicons biomarker discovery associated to IBD and IBS compared to CTRLs on biopsy specimens.

Linear discriminant analysis effect size employs the non-parametric factorial Kruskal-Wallis sum-rank test (α = 0.05) to identify taxa with significantly different abundances between categories, followed by LDA to estimate the effect size of each feature of the differential abundance. The differences in abundance were regarded as statistically significant when the logarithmic LDA score was \>2.0. If multiple varieties with different ranks showed significance in the same taxon, the lowest-ranked varieties were regarded as responsible.

Results {#S3}
=======

Study Population {#S3.SS1}
----------------

A total of 129 individuals were recruited in this study as part of the research project (code: WFR- GR-2011-02350817) financed by the Ministry of Health (Italy). Specifically, 38 (29.5%) IBD patients from the Department of Medicine and Gastroenterology of Tor Vergata Hospital, 44 (34.1%) IBS patients, and 47 (36.4%) CTRL subjects from the Gastroenterology Unit of the Campus Bio-Medico Hospital (Rome, Italy) were enrolled from 2015 to 2017.

The median age of the study population was 51 years (44--56) (p25 and p75, respectively). Males represented 48% of the study population. The demographic and clinical characteristics of IBD and IBS patients and of CTRLs are shown in [Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}. The IBS population showed a predominance of female patients, compared to IBD and CTRLs, and due to the prevalence of the disease.

###### 

The demographic and clinical characteristics of IBD patients.

  **IBD Patient Characteristics**                    **IBD**
  -------------------------------------------------- -------------
  Crohn's disease                                    7
  Ulcerative colitis                                 31
  Age, years median (range)                          48 (21--74)
  Sex, male N (%)                                    21 (55.2%)
  **Smoking habits, N (%)**                          
  Yes                                                2 (5.3%)
  No                                                 36 (94.7%)
  **Disease activity in UC patients, N (%)^a^**      
  Remission                                          3 (9.6%)
  Mild                                               7 (22.6%)
  Moderate                                           11 (35.6%)
  Severe                                             10 (32.2%)
  **Disease activity in CD patients, N (%)^b^**      
  Remission                                          2 (28.6%)
  Mild                                               0
  Moderate                                           3 (43.8%)
  Severe                                             2 (28.6%)
  **CD behavior, N (%)**                             
  B1: Inflammatory                                   2 (28.6%)
  B2: Stricture                                      5 (71.4%)
  B3: Penetrating                                    0
  **CD location, N (%)**                             
  L1: Ileal                                          5 (71.4%)
  L2: Colonic                                        1 (14.3%)
  L3: Ileocolonic                                    1 (14.3%)
  **UC location, N (%)**                             
  E1: Proctitis                                      2 (6.4%)
  E2: Left-sided                                     14 (45.2%)
  E3: Extensive                                      15 (48.4%)
  **Endoscopist assessment of severity, N (%)^c^**   
  Mild                                               8 (21.1%)
  Moderate                                           13 (34.2%)
  Severe                                             17 (44.7%)
  **Previus surgery, N (%)**                         
  CD: Ileo colonic resection                         3 (42%)
  UC                                                 0
  **Concomitant medication, N (%)**                  
  5-aminosalicylic acid or sulfasalazine             20 (51.6%)
  TNFs alone                                         3 (7.8%)
  Thiopurine alone                                   2 (5.3%)
  Steroids alone                                     11 (28.9%)
  Steroids plus anti-TNF                             2 (6.4%)

a, adapted from Truelove & Witts; b, adapted from Harvey-Bradshaw Index; c, adapted from Mayo endoscopic score for UC patients or simple endoscopic score for CD patients; NA, not applicable.

###### 

The demographic and clinic characteristics of IBS patients and control subjects.

  **Subject characteristics**      **IBS (*N* = 44)**   **CTRLs (*N* = 47)**   
  -------------------------------- -------------------- ---------------------- ---------
  Sex, N (%)                       Male                 14 (32)                27 (57)
                                   Female               30 (68)                20 (43)
  Predominant bowel habit, N (%)   Diarrhea             16 (36)                NA
                                   Constipation         18 (41)                NA
                                   Alternating          10 (23)                NA
  Concomitant therapies, N (%)     Antispasmodics       7 (16)                 0
                                   Antidepressant       3 (7)                  1 (2)
                                   Laxatives            8 (18)                 0

NA, not applicable.

Fecal and Mucosal Sample Collections {#S3.SS2}
------------------------------------

A total of 107 fecal samples were included in this study and processed, specifically 30 from IBD patients, 36 from IBS patients, and 41 from CTRLs (22 subjects did not collect fecal samples).

A total of 142 biopsy specimens were obtained from 126 subjects. Specifically, 45 biopsies from CTRLs, 44 from IBS patients and 53 from IBD patients (37 from inflamed intestinal areas, and 16 from not inflamed areas) were collected.

Fecal Microbiota Composition and Distribution {#S3.SS3}
---------------------------------------------

A total of 307,036.00 sequencing reads were obtained from the 107 fecal samples. The differences of microbiota in IBD, IBS, and CTRLs were measured by the α- and β-diversities. In stool samples, the microbiota richness, based on the Shannon and Chao I indexes, was characterized by a diversity reduction going from CTRLs to IBS to IBD ([Table 3](#T3){ref-type="table"}).

###### 

Fisher's least significant difference (LSD) test on α-diversity indexes.

  **Stool**           **Biopsy**                                        
  ------------------- ------------ --------------- ------- ------------ ---------------
  **Shannon index**                                                     
  CTRL                **5.14**     **0**.**000**   CTRL    **4.25**     **0**.**000**
  IBD                 **4.06**                     IBD     **3.45**     
  CTRL                5.14         0.284           CTRL    4.25         0.649
  IBS                 4.92                         IBS     4.16         
  IBD                 **4.06**     **0**.**000**   IBD     **3.45**     **0**.**017**
  IBS                 **4.92**                     IBS     **4.16**     
                      IBD I^\*^    3.05            0.878                
                      IBD NI^\*^   3.16                                 
  **Chao1 index**                                                       
  CTRL                **365.05**   **0**.**012**   CTRL    **156.29**   **0**.**001**
  IBD                 **244.56**                   IBD     **98.67**    
  CTRL                365.05       0.108           CTRL    156.29       0.367
  IBS                 292.24                       IBS     140.17       
  IBD                 **244.56**   **0**.**012**   IBD     **98.67**    **0**.**017**
  IBS                 **292.24**                   IBS     **140.17**   
                      IBD I^\*^    103.98          0.221                
                      IBD NI^\*^   67.83                                

\*

I, inflamed; NI, not Inflamed.

p

values \< 0.05 are reported in bold.

β-diversity analyses, performed by unweighted and weighted UniFrac algorithms, performed on all fecal samples, showed the IBD cluster, separated from CTRLs and IBS samples, that resulted intermixed ([Supplementary Figures S1A,B](#TS1){ref-type="supplementary-material"}). β-diversity analyses, performed on IBD, and CTRLs showed a clear separation between the two groups (PERMANOVA *p* = 0.001 for both analyses) ([Supplementary Figures S2, S3A](#TS1){ref-type="supplementary-material"}). The same result was obtained forIBD and IBS comparison (PERMANOVA *p* = 0.001 and *p* = 0.002, respectively) ([Supplementary Figures S2, S3C](#TS1){ref-type="supplementary-material"}). A not significant separation between IBS and CTRLs (PERMANOVA *p* = 0.13 and *p* = 0.053, respectively) was reported ([Supplementary Figures S2, S3B](#TS1){ref-type="supplementary-material"}).

Phylum distribution in IBD harbored less bacteroidetes and Verrucomicrobia (*p* \< 0.05) than CTRLs ([Figure 1A](#F1){ref-type="fig"}), while in IBS bacteroidetes appeared increased compared to CTRLs (*p* \< 0.05) ([Figure 1B](#F1){ref-type="fig"}). When compared IBS and IBD samples, a significant increase of bacteroidetes (pFDR \< 0.05) and Verrucomicrobia (*p* \< 0.05) and a reduction of Actinobacteria (*p* \< 0.05) was observed in IBS ([Figure 1C](#F1){ref-type="fig"}).

![Bar chart reporting Kruskal-Wallis test results on OTUs grouped at taxonomic level of phylum for IBD vs. CTRL **(A)**, IBS vs. CTRL **(B)**, and IBD vs. IBS **(C)**, in fecal samples. Fecal samples have been grouped and averaged in the comparisons IBD vs. CTRL **(A)**, IBS vs. CTRL **(B)**, and IBD vs. IBS **(C)**. Each column in the plot represents a group, and each color in the column represents the percentage of relative abundance for each phyla.](fmicb-10-01655-g001){#F1}

Kruskal-Wallis test showed that *Ruminococcus, Streptococcus, Lactobacillus* were significantly represented in IBD vs. CTRLs (pFDR \< 0.05), while Ruminococcaceae, Lachnospiraceae, Rikenellaceae, and *Oscillospira* were underrepresented in IBD (pFDR \< 0.05) ([Figure 2A](#F2){ref-type="fig"} and [Supplementary Table S1](#TS1){ref-type="supplementary-material"}). *Akkermansia muciniphila* was reduced in IBD compared to CTRLs (pFDR \< 0.05).

![Bar chart reporting Kruskal-Wallis test results on OTUs grouped at taxonomic level of families/species for IBD vs. CTRL **(A)**, IBS vs. CTRL **(B)**, and IBD vs. IBS **(C)**, in fecal samples. Fecal samples have been grouped and averaged in the comparisons. For the IBD vs. CTRL **(A)** comparison, only OTUs that showed pFDR \< 0.05 and relative abundance \>0.01 were reported. For the IBS vs. CTRL **(B)** only OTUs that showed *p* \< 0.05 were reported. For the IBD vs. IBS **(C)** comparison, only OTUs that showed pFDR \< 0.05 were reported. B, Bacteroidetes, F, Firmicutes, P, Proteobacteria.](fmicb-10-01655-g002){#F2}

In IBS samples, *Parabacteroides distasonis* was increased, while *Lactococcus* and *Pseudomonas* were reduced compared to CTRLs (*p* \< 0.05) ([Figure 2B](#F2){ref-type="fig"} and [Supplementary Table S1](#TS1){ref-type="supplementary-material"}).

When compared IBS and IBD samples, *Bacteroides*, *Oscillospira*, Rikenellaceae, *Butyricimonas*, *Roseburia*, Mogibacteriaceae, Barnesiellaceae, *Anaerostipes*, and *P. distasonis*, *Parabacteroides* were more abundant in IBS (pFDR \< 0.05) than in IBD, while *Granulicatella* was less abundant ([Figure 2C](#F2){ref-type="fig"} and [Supplementary Table S1](#TS1){ref-type="supplementary-material"}). *A. muciniphila* was reduced in IBD compared to IBS (*p* \< 0.05).

Mucosal Microbiota Composition and Distribution {#S3.SS4}
-----------------------------------------------

A total of 130,330.00 sequencing reads were obtained from 142 mucosal samples.

Similarly, to fecal samples, biopsy α-diversity showed decreasing values from CTRLs to IBD through IBS ([Table 3](#T3){ref-type="table"}). No significant difference was observed between IBD inflamed and not inflamed tissue samples ([Table 3](#T3){ref-type="table"}).

β-diversity analyses, performed by unweighted and weighted UniFrac algorithms, performed on all mucosal samples, showed a separation between IBD (inflamed tissue) and CTRLs and between IBD (inflamed tissue), and IBS (but a less separation between IBS and CTRLs ([Supplementary Figures S4A,B](#TS1){ref-type="supplementary-material"}). This result was confirmed by PERMANOVA tests, applied on both Unweighted and Weighted distant matrices, performed separately on IBD (inflamed tissue) vs. CTRLs (*p* = 0.001 for both analyses), IBD vs. IBS (*p* = 0.001 for both analyses), and IBS vs. CTRLs (*p* = 0.092 and *p* = 0.084, respectively) ([Supplementary Figures S5, S6A--C](#TS1){ref-type="supplementary-material"}). No significant difference was observed between IBD inflamed and not inflamed tissue samples (PERMANOVA *p* value = 0.94 and 0.36, respectively) ([Supplementary Figures S5, S6D](#TS1){ref-type="supplementary-material"}).

Inflamed mucosa microbiota of IBD patients harbored more Proteobacteria (pFDR \< 0.05), and less bacteroidetes (pFRD \< 0.05) and firmicutes (*p* \< 0.05) respect to CTRLs ([Figure 3A](#F3){ref-type="fig"}). In IBS, bacteroidetes were increased compared to CTRLs (*p* \< 0.05) ([Figure 3B](#F3){ref-type="fig"}) and compared to IBD inflamed mucosa (*p* \< 0.05) ([Figure 3C](#F3){ref-type="fig"}). No statistical difference was observed comparing inflamed vs. not inflamed IBD mucosa ([Figure 3D](#F3){ref-type="fig"}).

![Bar chart reporting Kruskal-Wallis test results on mucosal OTUs grouped at taxonomic level of phylum for IBD vs. CTRL **(A)**, IBS vs. CTRL **(B)**, IBD vs. IBS **(C)**, and IBD inflamed vs. not inflamed **(D)**. Mucosal samples have been grouped and averaged in the comparisons IBD inflamed vs. CTRL **(A)**, IBS vs. CTRL **(B)**, IBD inflamed vs. IBS **(C)**, and IBD inflamed vs. not inflamed **(D)**. Each column in the plot represents a group, and each color in the column represents the percentage of relative abundance for each phyla. *p* values corrected for FDR were highlighted by star.](fmicb-10-01655-g003){#F3}

At genus/species level, an increase of Enterobacteriaceae (pFDR \< 0.05) and a reduction of *Bacteroides*, *P. distasonis*, Rikenellaceae, *Coprococcus*, and Lachnospiraceae were observed in IBD inflamed mucosa compared to CTRLs (pFDR \< 0.05) ([Figure 4A](#F4){ref-type="fig"} and [Supplementary Table S2](#TS1){ref-type="supplementary-material"}). Moreover, also *Faecalibacterium prausnitzii* and Ruminococcaceae were decreased in IBD (*p* \< 0.05). An increment of *Prevotella copri*, *Eubacterium dolichum*, *Veillonella dispar*, and *Haemophilus parainfluenzae*, and a reduction of *Anaerostipes* were reported in IBS samples compared to CTRLs (*p* \< 0.05) ([Figure 4B](#F4){ref-type="fig"} and [Supplementary Table S2](#TS1){ref-type="supplementary-material"}). In the comparison between IBS and IBD inflamed mucosa, *Bacteroides*, Lachnospiraceae, *Parabacteroides*, *P. distasonis*, Rikenellaceae, *Coprococcus*, and *Ruminococcus* appeared increased in IBS, though Enterobacteriaceae, Enterococcaceae were reduced in IBS respect to IBD ([Figure 4C](#F4){ref-type="fig"} and [Supplementary Table S2](#TS1){ref-type="supplementary-material"}). The intra-individual comparison between inflamed vs. not inflamed IBD mucosa was focused only on the OTUs with relative abundance \>0.01. In this comparison *Bacteroides*, Ruminococcaceae, *Bacteroides fragilis*, *Sutterella*, Paraprevotellaceae, *Faecalibacterium prausnitzii*, *H. parainfluenzae*, Lachnospiraceae, and *P. copri* were decreased in IBD inflamed mucosa. Enterobacteriaceae, *Prevotella*, Enterococcaceae, *Oscillospira*, and *Blautia* were increased in IBD, even if the *p* value was not significant ([Figure 4D](#F4){ref-type="fig"} and [Supplementary Table S2](#TS1){ref-type="supplementary-material"}).

![Bar chart reporting Kruskal-Wallis test results on mucosal OTUs of families/species for IBD inflamed vs. CTRL **(A)**, IBS vs. CTRL **(B)**, IBD inflamed vs. IBS **(C),** and IBD inflamed vs. not inflamed **(D)**. For the IBD inflamed vs. CTRL **(A)** comparison only OTUs that showed pFDR \< 0.05 and relative abundance \>0.01 were reported. For the IBS vs. CTRL **(B)** only OTUs that showed *p* \< 0.05 were reported. For the IBD vs. IBS **(C)** comparison, only OTUs that showed pFDR \< 0.05 and relative abundance \>0.01 were reported. For the IBD inflamed vs. not inflamed biopsies only OTUs that showed a relative abundance \>0.01 were reported **(D)**. B, Bacteroidetes, F, Firmicutes, P, Proteobacteria.](fmicb-10-01655-g004){#F4}

Mucosa Versus Stool Microbiota Comparison {#S3.SS5}
-----------------------------------------

Unweighted and Weighted β-diversity analyses showed a clear and significant separation between mucosa and stool samples in all groups ([Supplementary Figures S7, S8A--C](#TS1){ref-type="supplementary-material"}). At phylum level, firmicutes and Actinobacteria distribution were increased, while bacteroidetes and Proteobacteria resulted decreased in stools from all groups (pFDR \< 0.05, data not shown). Verrucomicrobia resulted higher in stool compared to mucosal samples (pFDR \< 0.05 for CTRL and IBS). When considering only stool samples Verrucomicrobia was more abundant in IBS samples.

Microbiota composition (filtered for pFDR \< 0.05 and relative abundance \>0.01), showed similar profile in CTRLs, and IBS for both mucosal and stool samples. IBD pattern was characterized by a different and specific signature.

In particular, in CTRL and IBS, *Bacteroides* and Lachnospiraceae were higher in mucosal samples, while Clostridiaceae, *Oscillospira*, Ruminococcaceae, and *Sutterella* were higher in stools ([Supplementary Figure S9](#TS1){ref-type="supplementary-material"} and [Supplementary Table S3](#TS1){ref-type="supplementary-material"}). In IBD, *Blautia*, Clostridiaceae, *Coprococcus*, Erysipelotrichaceae, *Lactobacillus*, and *Streptococcus* were higher in stools respect to mucosal samples (*p* \< 0.05) ([Supplementary Figure S9](#TS1){ref-type="supplementary-material"} and [Supplementary Table S3](#TS1){ref-type="supplementary-material"}).

Comparison of Taxonomic Composition According to Disease Status by LEfSe for 16S rRNA-Based Metagenomic Biomarker {#S3.SS6}
-----------------------------------------------------------------------------------------------------------------

The linear discriminant analysis effect size analysis on the taxonomic composition performed on biopsy samples and comparing all groups showed a higher number of OTUs featuring the IBD/CTRL pair ([Supplementary Figures S10A--C](#TS1){ref-type="supplementary-material"}).

Considering LEfSe results, we selected the OTUs exclusively associated to each group, or shared between different groups ([Figure 5](#F5){ref-type="fig"}). The *Anaerostipes* and Ruminococcaceae were identified as potential biomarkers for CTRL microbiota Erysipelotrichi for IBS and Gammaproteobacteria, *Enterococcus*, Enterococcaceae for IBD ([Figure 5](#F5){ref-type="fig"}). *V. dispar* was identified both in IBS and IBD, meanwhile *Ruminococcus*, *Sutterella*, *Odoribacter*, *P. distasonis*, *Coprococcus*, Lachnospiraceae, Bacteroidales, Bacteroidia, and Bacteroidetes were identified in CTRLs as well as in IBS. LEfSe analysis confirmed the results of Kruskal-Wallis test for Ruminococcaceae, *P. distasonis*, *Coprococcus* and Lachnospiraceae.

![Descriptive model of microbiota composition and its role starting from eubiosis to dysbiosis based on biopsy samples. Model suggests that, in eubiosis condition, specific OTUs compose microbiota and maintain equilibrium. A microbiota alteration trigs the inflammation, leading to an increment of Erysipelotrichi and a reduction of secondary bile acid production. Then a further increment of inflammation leads to increase of primary bile producers with the consequence of dysbiosis.](fmicb-10-01655-g005){#F5}

Gut Microbial Profiling and Clinical Features in IBD and IBS {#S3.SS7}
------------------------------------------------------------

Unweighted and Weighted β-diversity analyses of IBD biopsy and fecal samples does not revealed a clustering between CD and UC samples (PERMANOVA test on Unweighted analysis *p* = 0.176 and *p* = 0.109, respectively; PERMANOVA test on Weighted analysis *p* = 0.226 and *p* = 0.096, respectively) ([Supplementary Figures S11, S12A,B](#TS1){ref-type="supplementary-material"}). Moreover, stratifying IBD samples for disease activities we do not obtain any statistical clustering (PERMANOVA test on Unweighted analysis *p* = 0.66 and *p* = 0.12, respectively: PERMANOVA test on Weighted analysis *p* = 0.176 and *p* = 0.686, respectively) ([Supplementary Figures S11, S12C,D](#TS1){ref-type="supplementary-material"}). Appling β-diversity analysis on IBS biopsy and fecal samples stratified for predominant bowel habits, we not obtain a clustering amongst diarrhea, constipation, and alternating sample group (PERMANOVA test on Unweighted analysis *p* = 0.206 and *p* = 0.091, respectively; PERMANOVA test on Unweighted analysis *p* = 0.509 and *p* = 0.251) ([Supplementary Figures S13, S14A,B](#TS1){ref-type="supplementary-material"}).

Discussion {#S4}
==========

In this study fecal and mucosal microbiota were characterized by 16S rRNA gene amplicons, in a large cohort of IBS and IBD patients compared to CTRLs. These subjects were enrolled from 2015 to 2017 in two hospitals in Rome.

The relatively low number of patients enrolled, considering the heterogeneity of the IBD and IBS populations and the presence of possibly confounding factors such as medications and diet represents a limitation of this study.

Several data available in literature reported different microbiota profiles in IBD and IBS patients, but those comparing mucosal and fecal microbiota are still lacking or controversial. This study could contribute to fill the gap of knowledge about the role of mucosal and fecal microbiota in inflammation in IBS or IBD patients.

As observed in previous studies ([@B57]; [@B68]; [@B7]; [@B28]), the microbiota ecological analyses revealed a significant decrease in richness related to the increasing bowel inflammation (CTRLs \> IBS \> IBD). Moreover, the β-diversity analyses and the phylum profiling revealed a more different microbiota profile between IBD and CTRL, respect to IBS and CTRL. These results could reflect the increasing inflammatory bowel status observed going from CTRL toward IBS and to IBD.

Moreover, our results showed that the mucosa associate bacteria are equally distributed between inflamed and not-inflamed tissue in the intra-individual comparison. [@B6], analyzing inflamed and non-inflamed biopsies by denaturing gradient gel electrophoresis (DGGE), reported high similar bacterial profiles between the two sample groups ([@B6]). The same conclusions were reported by other authors that analyzed biopsy samples of ulcerated and non-ulcerated mucosa of IBD patients by temporal temperature gradient gel electrophoresis (TTGE) ([@B66]; [@B69]; [@B74]). Finally, also [@B23], by high-throughput sequencing of 16S rRNA cloned libraries, reported that there is not a localized dysbiosis in IBD between inflamed and non-inflamed tissue ([@B23]). Indeed, in line with our study, the differences in bacterial composition were not due to the inflamed condition of the tissue but the bacteria associated with the mucosal surface seems to be related to the specific disease and to the systemic inflammation condition.

In controls, the most represented species of fecal microbiota were Ruminococcaceae, *Oscillospira* and Lachnospiraceae as supported by other studies ([@B44]; [@B62]; [@B1]).

In patients with IBS the fecal microbiota was characterized by the presence of *Oscillospira*, which, interestingly, has been already described in normal mucosa or in case of mild inflammation ([@B23]).

We showed the reduction of *A. muciniphila* in fecal microbiota of IBD patients, compared to CTRLs and IBS, as also previously reported ([@B4]). This species exerts beneficial effects in the host ([@B19]; [@B12]; [@B53]). It has been found negatively correlated with IBD ([@B56]; [@B58]) and IBS ([@B22]), suggesting its protective role when abundant in the microbiota composition. Furthermore, in an animal model harboring a human intestinal microbiota, the presence of this microorganism reduces colonic histological damages, and tissue mRNA expression of pro-inflammatory mediators ([@B22]).

When looking at mucosal microbial composition, *V. dispar*, *P. copri* and *H. parainfluenzae* were significantly represented only in IBS mucosal microbiota. Regarding *V. dispar*, it has generally been considered a non-pathogenic bacteria, but recently, Kasai and co-workers suggested a possible role in inflammation and in colorectal cancer ([@B35]). Moreover, *P. copri* has been associated to enhancing susceptibility to inflammatory disorders like arthritis through intrinsic Th17 promoting capability, driving cytokines IL-6 and IL-23 ([@B64]) and has been associated to systemic inflammation status too ([@B10]; [@B55]). A recent study showed that *P. copri* enhances dextran sulfate sodium-induced colitis in mice, in association with increased IFN-γ production, suggesting that *P. copri* promotes Th1 immune responses in experimental colitis ([@B39]).

In our study Enterobacteriaceae and *Streptococcus* were associated to IBD microbiota. The possible involvement of *Streptococcus* in the inflammatory status of IBD was already suggested by other studies that reported the interaction of streptococcal virulence factors with immune cells eliciting inflammatory response in different organs ([@B26]; [@B61]).

Regarding Enterobacteriaceae, previous studies have found elevated abundance of this family in Crohn's Disease patients ([@B71]; [@B24]; [@B5]; [@B67]; [@B32]; [@B54]), supporting our data.

By the LEfSe analyses we propose a model based on the potential bacterial biomarkers associated to mucosal inflammation. In this model ([Figure 5](#F5){ref-type="fig"}), *Anaerostipes* and Ruminococcaceae were exclusively associated to CTRL microbiota. The healthy role of these bacteria is probably exerted through the production of short chain fatty acids (SCFA) ([@B41]; [@B11]). Interestingly, CTRL and IBS share the presence of *Ruminococcus*, *Sutterella*, *Odoribacter*, *P. distasonis*, *Coprococcus*, Lachnospiraceae, and Bacteroidales that are commonly recognized as commensals ([@B72]; [@B27]). Moreover, Wang and co-workers correlated high levels of *Odoribacter*, *Sutterella*, *Coprococcus*, *Lachnospira*, and *Ruminococcus* with the improvement of health status in CD patients, leading to suppose a positive role against gut inflammation ([@B75]). Erysipelotrichi were exclusively present in IBS mucosal samples. Of interest, overgrowth of several bacteria such as Erysipelotrichi is induced, in an animal model, by administration of cholic acid, which has been reported to be increased in IBS patients ([@B30]; [@B14]).

The mucosal microbiota of IBS shares the presence of *V. dispar* with IBD. *V. dispar* showed the ability to degrade cholate and deoxycholate in secondary products ([@B2]; [@B14]). The association of this species to IBD and IBS suggests a role of these bacteria in dysmetabolism of bile acids reported in IBD and IBS ([@B13]). Actually, in IBD patients was reported a decrease of secondary biliary acids with a related loss of their anti-inflammatory effects, thus suggesting biliary acids as important players in the pro-inflammatory processes ([@B15]).

Finally, we reported that *Enterococcus*, Enterococcaceae, Gammaproteobacteria are exclusively present in IBD patients. It is well known that *Enterococcus faecalis* was the only human commensal to induce IBD ([@B49]); and that the Gammaproteobacteria ([@B20]) (e.g., *E. coli* AIEC, *Klebsiella* spp., *Pseudomonas* spp., and *Salmonella*) overgrew in mucosa of IBD patients ([@B47]).

The knowledge of microbiota composition in patients with IBD and IBS is largely debated. In this panorama, this study provides an overview of the alterations of microbiota in stool and mucosal samples from IBD and IBS patients in relation of inflammation grading existing between the two diseases. Moreover, the potential mucosal biomarkers identified in this study, could be evaluated as actors in the IBD and IBS intestinal inflammation and then considered in the development of new clinical interventions for the prevention and treatment of IBD and IBS, based on microbiota modulation.
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